protein
| interacting with VDR, CDH1 and TCF8 in carcinogenesis (overexpression of SNAI1 repressing VDR and CDH1) |
|
interacting with VDR and TCF8 in colorectal cancer (loss of VDR and TCF8 and presence of SNAI1 is predictor of poor clinical prognosis) |
|
interacting with PEBP1 (novel component of the SNAI1 transcriptional regulatory network important for the progression and metastasis of cancer) |
|
interacting with PRMT5, effector recruited to SNAI1 through an interaction with JUB that functions to repress the SNAI1 target gene, CDH1 |
|
interacting with SUZ12 (SNAI1 increases the binding of SUZ12 to the CDH1 promoter and the trimethylation of lysine 27 in histone H3) |
|
binding to HMGA2 |
|
can bind to an E-box of the myosin Va promoter and induce its activity, which indicates that SNAI1 might act as a transcriptional activator |
|
interacted with histone lysine-specific demethylase 1 (KDM1A)(SNAG domain of SNAI1 and the amine oxidase domain of KDM1A were required for their mutual interaction) |
|
interaction with the KDM1A/RCOR1 complex is critical for the stability and function of SNAI1 |
|
SNAI1 controls ZEB1 expression at multiple levels and acts cooperatively with TWIST1 in the ZEB1 gene transcription induction |
|
PTK2 is a novel regulator of SNAIL1-dependent epithelial-mesenchymal transition in embryonic cells |
|
NOTCH1 intracellular domain (NICD) is a novel SNAIl-binding partner, and this interaction was found to induce ubiquitination and MDM2-dependent degradation of SNAI1, and NOTCH1 binds and induces degradation of SNAIl in hepatocellular carcinoma |
|
SNAI1 enhances the binding of AKT2 to the E-cadherin (CDH1) promoter and AKT2 interference prevents SNAI1 repression of CDH1 gene |
|
PRDX1 regulated the expression of two E-cadherin transcriptional repressors, SNAI1, SNAI2 |
|
regulates MYOD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis |
|
AXIN2 acts as a potent promoter of carcinoma behavior by up-regulating the activity of the transcriptional repressor, SNAI1, inducing a functional epithelial-mesenchymal transition (EMT) program and driving metastatic activity |
|
PRKD1 efficiently interacts with SNAI1 in nuclei |
|
binds to E-boxes in the ESRP1 promoter, causing repression of the ESRP1 gene |
|
down-regulates PTGS2 |
|
SNAI1 inhibits NOTCH1 intracellular domain mediated transcriptional activation via competing with MAML1 |
|
SNAI1 binds to the promoter of the OTUD7A gene and mediates the direct consequence of OTUD7A repression |
|
DYRK2 regulates cancer invasion and metastasis by degrading SNAI1 |
|
ETV1 promotes SNAI1 expression to induce EMT-like metastatic progression in gastric cancer |
|
FBXL5 is a novel SNAI1 ubiquitin ligase |
|
SNAI1 regulates heterochromatin transcription through LOXL2, thus creating the favorable transcriptional state necessary for completing EMT (epithelial-to-mesenchymal transition) |
|
SNAI1 C2H2-type zinc-finger (ZF) domain functions both as a nuclear localization signal which binds to KPNB1 directly and as a DNA-binding domain |
|
SNAI1-DLL4/NOTCH1 axis controls embryonic vascular development |
|
SNAI1 recruits RNF2 to mediate transcriptional repression and cell migration in pancreatic cancer cells |
|
PCDH9 is a novel regulator of EMT by increasing the activity of GSK3B and inhibiting SNAI1 |
|
HMG20A together with KDM1A are required for SNAI1-dependent repression of epithelial genes and for TGFB1-triggered EMT |
|
VANGL1 induced the expression of the epithelial-mesenchymal transition (EMT) markers (N-cadherin, ZEB1, ZEB2, SNAI1 and SNAI2) as well as the glioma stemness markers (CD133, ALDH1 and EPHB1) |
|
represses TDGF1 gene by direct transcriptional interaction and it co-ordinately regulates likely cell fate decisions during development and could be causal of cancers) |
|
important role for KDM8 in breast cancer through the regulation of SNAI1 |
|
MAPK14 mediates epithelial-mesenchymal transition by regulating SUP20TH and SNAI1 in Head and Neck squamous cell carcinoma |
|
KRT18 critically contributes to initiating TGFB1-induced EMT via the SMAD2/3 -mediated regulation of SNAI1, SNAI2 expression in breast epithelial cells |
|
ANXA1 promotes the proliferation of esophageal squamous cell carcinoma (ESCC) cells, and increases the expression of SNAI1, whereas it inhibits that of CDH1, thus enhancing the migration and invasion of ESCC cells |
|
SPSB3 is a novel E3 ligase component that targets SNAI1 into polyubiquitination and degradation in response to GSK3B phosphorylation of SNAI1 |
|
CTDSPL2 acts as a novel SNAI1 phosphatase |
|
enhanced PAPSS2/VCAN sulfation axis is essential for SNAI1-mediated breast cancer cell migration and metastasis |
|
LAMP2 attenuates EMT by suppressing SNAI1 expression in hepatocellular carcinoma (HCC) |
|
FSCN1 promote Epithelial-mesenchymal transition (EMT) through SNAI1 in ovarian cancer cells |
|
SNAI1 elicits collective migration in squamous cell carcinoma by inducing the expression of a tight junctional protein, CLDN11 |
|
|